NATALEE: Adjuvant ribociclib maintains overall health-related quality of life across nodal and anatomical stage subgroups at five years

Skin Cancer

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Eur J Cancer

Helgadottir H, Ny L, Ullenhag GJ, Mikiver R, Isaksson K, Olofsson Bagge R

doi: 10.1016/j.ejca.2025.116201

Gynecologic Cancer

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

J Natl Cancer Inst

Joly F, Anota A, Chabaud S, Cropet C, Priou F, Harter P, Pignata S, Palacio I, Petru E, Kobayashi H, Vergote I, Parma G, Mäenpää J, Raymond E, Ataseven B, Pisano C, Lainez N, Tsibulak I, Yonemori K, Vuylsteke P, Lapresa MT, Mirza MR, Bouchaert P, Buderath P, Lorusso D, Herrero A, Eberst L, Burges A, Scambia G, Ortega E, Guillemet C, Pujade-Lauraine E, Kurtz JE, Ray-Coquard I

doi: 10.1093/jnci/djag122

Leukemia

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab

Br J Haematol

Allsup DJ, Cairns DA, Samy EF, Duley L, Bloor A, Varghese A, Meads D, Dawkins B, Girvan S, Howard DR, Hockaday A, Brown JM, Jackson S, Greatorex N, Templeton P, Tupper M, Phillips D, Yaqub S, Mortimer D, Stones D, Patten PEM, Rawstron A, Hillmen P, Munir T

doi: 10.1111/bjh.70416

CHICAGO 2026

Breast Cancer

NATALEE: Gene expression analysis supports ribociclib plus NSAI across PAM50 intrinsic subtypes in HR-positive, HER2-negative early breast cancer

Genitourinary Cancer

Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

Lancet Oncol

Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O

doi: 10.1016/S1470-2045(25)00189-5

Lung, Respiratory and Thoracic Cancer

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

J Thorac Oncol

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov K, Wu MF, Akewanlop C, Vu HV, Lee KH, Huang X, Armenteros-Monterroso E, Rukazenkov Y, Herbst RS

doi: 10.1016/j.jtho.2026.104179

Genitourinary Cancer

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

Lancet Oncol

Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F

doi: 10.1016/S1470-2045(26)00014-8

COMMENTED

Breast Cancer

Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial

★ 1 Recommended and commented by Dr Andreas Müller, Faculty Member

J Natl Cancer Inst

Wortelboer N, Kent S, Blommestein HM, van Ommen-Nijhof A, van der Noort V, van den Pol E, Páez CG, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van de Mheen CVS, Tol J, Driel CST, Vrijaldenhoven S, van Leeuwen-Stok AE, Sonke GS, Jager A, Konings IR

doi: 10.1093/jnci/djaf334

Lymphoma

Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Leuk Lymphoma

Lin Y, Palivela M, Lakzadeh P, Limbrick-Oldfield E, Wade SW, Hsu H, Kanters S, Sanderson R

doi: 10.1080/10428194.2026.2695323

Related content